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ABSTRACT
Bacteria and their metabolites are shown to be a potential therapeutic agent for cancer treatment. Much attention 
has been directed to Lactic acid bacteria (LAB) which exhibits several killing mechanisms via invasion and coloni-
zation of solid tumors. Discovery of the characteristics of postbiotic metabolites that exert the same probiotic effects 
has attracted immense attention towards anti-cancer effect. It is known that LAB improves health and composition 
of microbiota in the gut. Supplementation of LAB is proven to enhance the host immunity and modulation of the 
immune system to fight diseases including cancers. Lactobacillus plantarum I-UL4 is the LAB species isolated from 
Malaysian fermented food, Tapai Ubi which capable of producing bioactive metabolic products.  In this review, 
the properties of UL4-PPM will be discussed including anti-microbial, anti-cancer and immunomodulatory effects. 
Overall, it would be beneficial to discover the potential effects of UL4-PPM to possibly serve as an alternative treat-
ment for cancer.
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Cancer is an emerging public health problem in 
developing countries and is the second most common 
disease leads to death in the United States. It is estimated 
that about 1,685,210 cases were expected in 2016 
which is approximately over 4,600 new cancer cases 
were diagnoses each day worldwide (1). Colorectal 
cancer (CRC) is the third most commonly diagnosed 
cancer among both men and women in the United 
States. In Malaysia, colorectal cancer is the second most 
common cancer in both males and females in 2016. It 
is estimated that 2600 cases in men while 2000 cases 
in women were reported in Malaysia with 1300 and 
1000 of mortality rate, respectively (2). Mortality due to 
colorectal cancer is increasing and has been reported as 
the fourth leading cause of cancer death worldwide (3). 
However, the reported incidence of colorectal cancer is 
higher in developed Asian countries such as Japan, South 
Korea, and Singapore compared to Malaysia and other 
developing Asian countries (4). Diet has been shown to 
reduce CRC incidence by approximately 80% as it has 
multiple effects which could alter the metabolome or 
metabolites composition of the host (5).
Despite the advancement in cancer discovery and 
therapy, cancer has remained a major burden of 
disease worldwide leading to high incidence of 
deaths. Furthermore, adverse side effects are generally 
associated with the currently available chemotherapeutic 
agents due to unspecific toxicity towards normal cells. 
Probiotics including LAB have been reported to promote 
health and can be a potential preventive and therapeutic 
agent (6). Probiotics are live microbial food supplements 
with the ability to beneficially affect the gut microbiota 
by attributing a variety of immunological and metabolic 
parameters. There are several well-defined mechanisms 
including alteration of normal microbial ecosystem 
composition, maintenance of  the functions of gut 
lumen epithelial barrier, and modulation of mucosal 
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and systemic immune responses of the host (7, 8). In 
addition, probiotics and their metabolite products, 
postbiotics, have been proposed as food supplements 
to promote health and intestinal composition, as well as 
therapeutic agents in inflammatory bowel disease (IBD) 
(9).
Recently, the potential of metabolite product synthesized 
from probiotics in exerting the probiotic effects outside 
living cells either using metabolite combinations (10) or 
in combination with other prebiotics has drawn a lot 
of attention (11). Metabolites have advantages in term 
of logistics as it is more stable as well as have a wider 
applications in food industries and as feed additives 
in livestock industries (12).  Metabolites from dietary 
sources have been shown to affect the metabolism of 
the whole body by direct or indirect interaction with 
intestinal mucosa from the luminal side (13). 
In this review article, the effects of proteinaceous 
postbiotic metabolite (PPM) produced by Lactobacillus 
plantarum I-UL4 namely afterward as UL4-PPM on anti-
microbial, immunomodulatory and anti-carcinogenic 
properties will be discussed accordingly. 
 
PROTEINACEOUS POSTBIOTIC METABOLITE FROM 
Lactobacillus plantarum I-UL4 (PPM-UL4)
LAB are abundantly present in fermented foods, 
vegetation, gastrointestinal (GI), oral cavity, and 
urogenital tract and are commonly associated with 
several health-promoting elements (8).  The ability 
of LAB to serve as a food preservatives is due to the 
production of anti-microbial metabolites by targeting 
cell wall or membrane of the organisms such as organic 
acids and bacteriocins (14). Bacteriocins such as 
pyocin, colicin and microcin are one of the inhibitory 
metabolites produced by LAB consisting of amino acids 
that essentially play a role as to prevent the growth of 
competing microorganisms, and have been proven to 
also possess antineoplastic activity (15).
Lactobacillus plantarum I-UL4 is one of the LAB 
species isolated from Malaysian fermented food, Tapai 
Ubi (16) which has the ability to produce bioactive 
metabolic compounds termed as postbiotics. UL4-PPM 
is a postbiotics or metabolite produced by Lactobacillus 
plantarum I-UL4 which is believed to exert the probiotic 
effects without living cells (10, 17). To date, not much 
study has been done on the postbiotics, which are 
metabolite products from the probiotics in cancer-
related study since it has been majorly described that 
LAB act as anti-cancer agent by modulating immune 
responses in in vitro and in-vivo studies (18-20). 
ANTIMICROBIAL PROPERTIES OF PPM-UL4 
A few studies have shown that UL4-PPM encouraged the 
growth, reduced plasma cholesterol and enhanced the 
population of indigenous LAB in the intestine and faeces 
of rats (12). It is associated with a reduction of lowered 
faecal pH and faecal Enterobacteriaceae counts after 
supplementation with UL4- PPM (12, 16, 21). Modler 
et al. (22) suggested that reduction in intestinal pH may 
influenced the progression of large-bowel cancer by 
preventing the growth of putrefactive bacteria in the gut.
UL4-PPM could be a potential alternative for antibiotic 
growth promoters (AGPs) as a study conducted in broilers 
shown that UL4-PPM improved growth performance, 
LAB count and the concentration of fecal volatile fatty 
acid, while reducing in the number of Enterobacteriaceae 
(17). In fact, it could be beneficial as some pathogenic 
bacteria are resistant to numerous antimicrobial agents 
and potentially lethal when transmitted to humans (23). 
Anti-microbial properties of UL4-PPM are mainly due 
to its bactericidal and bacteriostatic effects that can kill 
pathogenic bacteria in gastrointestinal microflora (17). 
Report have also shown that increased in villi surface 
would increase nutrient absorption in small intestine 
(24).
IMMUNOMODULATORY AND ANTI-
CARCINOGENIC ATTRIBUTES BY PPM-UL4
There are several established drugs for standard first 
line therapy for CRC such as irinotecan, oxaliplatin 
and cetuximab. Nevertheless, the drugs have various 
adverse side effects. Therefore, much attention has been 
focused on the development of natural product-based 
anticancer agents that have the advantages as they are 
believed to have lesser side effects. LAB was found to 
improve gastrointestinal microbial population (25), exert 
antimicrobial activities and anti-carcinogenic properties 
(26). For example, azurin is a well-characterized 
bacteriocin discovered to exhibit cytostatic and 
apoptotic effect against human colon cancer cells (27). 
In addition, colicins which are metabolites produced by 
Escherichia coli has been shown to induce cell death in 
tumor cells by targeting the proteins located on the outer 
surface of the cells through antibody recognition (28, 
29). Thus, these bacteriocins are believed to specifically 
target tumor cells (30).
The anti-cancer activities of UL4-PPM towards a breast 
cancer cell line has been reported in 2015 (31). The 
similar properties have been proposed for LAB mediated 
activation of immune response and metabolic activity 
in colon cancer cells (32).  Even though several studies 
have clearly demonstrated the chemopreventive effects 
of dietary supplements of LAB against the development 
of colon cancer (33-35), however the chemopreventive 
and inhibitory effects of postbiotics or metabolite 
products from probiotics on colon cancer is very limited. 
Recently, probiotic metabolites have been shown to 
affect various functions at the cellular and molecular 
level including the initiation and progression of colon 
cancer which they may lead and regulate various 
83Mal J Med Health Sci 15(SP2): 81-84, July 2019
metabolic signaling pathways. Signaling pathway 
involve are crucially responsible for cell proliferation, 
invasion, apoptosis, inflammation, angiogenesis, and 
ultimately cancer metastasis (13, 35). A few evidences 
have demonstrated that metabolites from probiotic 
cultures could reduce cell proliferation of human 
colon cancer cells (36, 37).  A study has shown that the 
colorectal cancer severity in azoxymethane-induced 
rats could be reduced substantially when treated with 
UL4-PPM in drinking water (38). In this study, treatment 
with UL4-PPM reduced the total number of aberrant 
crypt foci (ACF) and crypt multiplicity, the incidence of 
tumor, adenoma and adenocarcinoma, with decreased 
expression of ß-catenin, indicating the reduction in the 
severity of colon cancer in animal colon cancer model. 
Modulation of microbial environment and several 
composition of the gut contribute to a better health status 
and providing beneficial effects to the host. Probiotic 
was found to reduce an inflammation in patients with 
gastrointestinal diseases (39). It has been demonstrated 
that tumor development and cancer metastasis may 
commonly occur in immunocompromised people. 
Thus, stimulation of the immune system may enhance 
host defense towards tumor cells which is also 
believed to be one of the most important mechanisms 
to treat the disease. UL4-PPM also has the ability to 
enhance the level of several cytokines or interleukins 
which are IFN-γ, TNF-α, IL-12 and IL-5 in serum and 
immune organs (spleen and thymus) that are crucially 
involve in the inhibition of colon carcinogenesis (38). 
Immunomodulatory activities of probiotics by regulating 
the production of anti- or pro-inflammatory interleukins 
(IL) resulted in the prevention of excessive immune 
response in inflammatory bowel diseases (40). Therefore, 
it is postulated that UL4-PPM may exhibit antineoplastic 
activity due to its immunomodulatory properties in the 
host.
CONCLUSION
UL4-PPM, the metabolites produced by L. 
plantarum I-UL4, has shown to exert anti-microbial, 
immunomodulatory and anti-carcinogenic properties 
in in vitro and in-vivo studies. Promisingly, UL4-PPM 
can be developed as a potential agent in prevention and 
treatment of CRC.
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